Summary by Futu AI
bluebird bio, Inc. has filed a notification of late filing with the Securities and Exchange Commission (SEC), indicating that it will not be able to submit its Quarterly Report on Form 10-Q for the period ended June 30, 2024, by the prescribed due date of August 14, 2024. The delay is attributed to the company's ongoing efforts to restate its financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. This restatement process has also affected the timely filing of its Annual Report for 2023 and the First Quarter Report for 2024. bluebird bio is working diligently to complete the restatement and file all outstanding reports as soon as possible. The company anticipates significant changes in its results of operations for the quarter ended June 30, 2024, compared to the same period in 2023, due to identified errors in lease and non-lease component accounting in agreements with contract manufacturing organizations. However, the company has stated that these errors are not expected to impact its cash position or revenue.
